AstraZeneca

News

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.

R&D

Gothenburg is Sweden's fastest-growing and second largest city region and one of Europe's leading innovation regions.

News

Prospects for AstraZeneca and Ionis' Wainua have been severely dented by a failed trial in ATTR cardiomyopathy, weighing on the shares of both firms.

News

AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.

News

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.

News

AstraZeneca has claimed a second approval for AKT inhibitor Truqap, in prostate cancer, that should help achieve its blockbuster hopes for the drug.